Vaccine for Use in Protecting a Pig Against Porcine Endemic Diarrhea Virus
AssigneesIntervet Inc., Universiteit Utrecht Holding B.V.
InventorsErwin Born, van den, Berend Jan Bosch, Peter Rottier
Life of this patent
Estimating the term…
Abstract
The invention pertains to a vaccine for use in protecting a pig against an infection with porcine endemic diarrhea virus (PEDV), the vaccine comprising non-live PEDV antigen and a non-metabolizable oil containing adjuvant, wherein the total amount of oil in the vaccine is less than 50% v/v, by administration of a dose of the antigen corresponding to at least 3.0E6 TCID50 killed whole PEDV. The invention also pertains to a method of protecting a pig against an infection with porcine endemic diarrhea virus.
Claims12
(canceled)
The method of claim 11, wherein the dose of the antigen corresponds to at least 1.5E7 TCID50 killed whole PEDV.
The method of claim 11, wherein the total amount of the oil is less than 40% v/v.
The method of claim 11, wherein the oil is emulsified in an hydrophilic solvent.
The method of claim 11, wherein the vaccine in addition to the non-metabolizable oil comprises vitamin E acetate.
The method of claim 11, wherein the antigen contains a polypeptide that corresponds to the C terminal two-third of the S1 domain of the spike protein of PEDV.
The method of claim 11, wherein the antigen is killed whole PEDV.
The method of claim 11, wherein the vaccine is for administration to a sow to protect the off-spring of this sow against an infection with porcine endemic diarrhea virus (PEDV).
A method to protect a pig against an infection with porcine endemic diarrhea virus (PEDV) comprising administering to the pig a vaccine comprising non-live PEDV antigen and a non-metabolizable oil containing adjuvant, wherein the total amount of oil in the vaccine is less than 50% v/v, and the antigen is administered at a dose corresponding to at least 3.0E6 TCID50 killed whole PEDV.
A vaccine to protect a pig against an infection with porcine endemic diarrhea virus (PEDV) comprising non-live PEDV antigen and a non-metabolizable oil containing adjuvant, wherein the total amount of oil in the vaccine is less than 50% v/v, and the antigen is present in a concentration corresponding to at least 1.5E6 TCID50 killed whole PEDV per ml.
Dependencies are inferred from the claim text.